


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



C-MER 希瑪

C-MER EYE CARE HOLDINGS LIMITED

希瑪眼科醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3309)

**CLARIFICATION ANNOUNCEMENT
IN RELATION TO
DISCLOSEABLE TRANSACTION
ACQUISITION OF THE ENTIRE EQUITY INTEREST
IN SHANGHAI LUCIDA MEDICAL**

Reference is made to the announcement of C-MER Eye Care Holdings Limited (the “**Company**”) dated 26 March 2019 in respect of the discloseable transaction in relation to the acquisition of the entire equity interest of Shanghai Lucida Medical Scientific Ltd. (上海璐視德醫療器械科技有限公司) (the “**Announcement**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

The Company wishes to clarify that, of the Consideration of RMB82.9 million (equivalent to HK\$97.3 million), 92.65% and 7.35% are payable to Renben Technology and Zhongmin Investment (being the Vendors) respectively in proportion to the equity interests to be acquired from them, and that the Vendors are, to the best of the Directors’ knowledge, information and belief having made all reasonable enquiries, Independent Third Parties both before and after Completion.

Save as disclosed above, all other information in the Announcement shall remain unchanged.

As Completion is subject to the fulfilment of a number of condition(s) precedent as set forth in the Acquisition Agreement, the Acquisition may or may not proceed. Shareholders and public investors should exercise caution when dealing in the securities of the Company.

By order of the Board
C-MER Eye Care Holdings Limited
Dr. LAM Shun Chiu
Chairman and Chief Executive Officer and Executive Director

Hong Kong, 30 April 2019

In this announcement, translation of RMB into HK\$ is based on the exchange rate of HK\$1: RMB0.8516.

As of the date of this announcement, the Board comprises four executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting, Dr. LEE Yau Wing Vincent and Mr. LI Chunshan and five independent non-executive Directors, namely Dr. LAU Johnson Yiu-Nam, Dr. LI Kwok Tung Donald, Mr. MA Chiu Cheung Andrew, Mr. CHAN Chi Leong and Ms. BENTLEY Annie Liang.